Table 1.
Variable | Pediatrics N = 60 | Adults N = 16 |
---|---|---|
Age, y, median (range) | 12 (2–17) | 34 (18–66) |
≤10 y | 23 (38.3%) | 0 |
>10 y | 37 (61.7) | 16 (100%) |
Body surface area, m2, median (range) | 1.2 (0.6–2.7) | 1.8 (1.1–2.7) |
Sex, n (%) | ||
Male | 37 (61.7) | 7 (43.8) |
Female | 23 (38.3) | 9 (56.3) |
Race | ||
Caucasian | 45 (75) | 14 (87.5) |
Asian | 4 (6.7) | 1 (6.3) |
Black | 4 (6.7) | 0 |
Other or missing (not specified) | 7 (11.7) | 1 (6.3) |
Karnofsky statusa / Lansky Play score, n (%) | 37 (62) / 23 (38) | 16 (100) / NA |
100 | 15 (25) / 11 (18.3) | 0 / NA |
90 | 6 (10) / 6 (10) | 8 (50) / NA |
80 | 7 (11.7) / 4 (6.7) | 5 (31.3) / NA |
70 | 3 (5) / 2 (3.3) | 1 (6.3) / NA |
<70 | 5 (8) / 0 | 2 (12.5) / NA |
Histology/cytology, n (%) | ||
Medulloblastoma | 39 (65) | 16 (100) |
Glioblastoma multiforme | 5 (8.3) | 0 |
Osteosarcoma | 5 (8.3) | 0 |
Rhabdomyosarcoma | 4 (6.8) | 0 |
Neuroblastoma | 3 (5.0) | 0 |
Hepatoblastoma | 1 (1.7) | 0 |
Anaplastic astrocytoma | 1 (1.7) | 0 |
Oligoastrocytoma | 1 (1.7) | 0 |
Gliomatosis | 1 (1.7) | 0 |
Time, mo, from initial diagnosis of primary site to start of study, median (range), n = 60 | 35.63 (8.6–111.6) | 70.72 (15.9–210.9) |
Time, mo, since most recent relapse/recurrence to start of study, median (range), n = 60 | 0.94 (0.3–7.2) | 1.61 (0.2–20.7) |
Prior therapy, n (%) | ||
Surgery | 59 (98.3) | 16 (100) |
Radiotherapy | 49 (81.7) | 16 (100) |
Chemotherapy | 60 (100.0) | 15 (93.8) |
aKPS missing for 1 (1.7) patient.